Viking Therapeutics: M&A Speculation Intensifies Amid Clinical Momentum
The shares of Viking Therapeutics have delivered a remarkable 34% gain over the past three months, signaling a powerful resurgence. ...
The shares of Viking Therapeutics have delivered a remarkable 34% gain over the past three months, signaling a powerful resurgence. ...
The pharmaceutical landscape for weight-loss treatments is witnessing a dramatic confrontation. As industry titans engage in a fierce price war, ...
As U.S. markets operated on a shortened post-Thanksgiving schedule, research departments remained active, with Viking Therapeutics generating significant analyst enthusiasm. ...
As US markets remain closed for the Thanksgiving holiday, shares of Viking Therapeutics are enjoying a brief respite. The stock ...
After a period of consolidation, Viking Therapeutics stock may be entering another phase of volatility. The biotech firm has scheduled ...
Viking Therapeutics has successfully completed patient enrollment for its pivotal VANQUISH-1 Phase 3 clinical trial ahead of schedule, marking a ...
The competitive landscape for anti-obesity medications has been jolted by a significant development from Viking Therapeutics. The biopharmaceutical company announced ...
Viking Therapeutics has achieved a significant advancement in its obesity treatment program, completing patient enrollment for its pivotal Phase 3 ...
Shares of Viking Therapeutics reached their highest point in ten months during Wednesday's trading session, continuing a significant upward trend. ...
Shares of Viking Therapeutics experienced significant upward momentum this week, fueled by renewed takeover speculation and a positive analyst update. ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.
© 2023 StocksToday.com